What sector does Bristol Myers Squibb belong to?

Bristol Myers Squibb operates in the Health Care sector, specifically the Pharmaceuticals industry, and is listed on the US markets.

What is the current share price of BMY?

As of the latest available quote, BMY traded at $63.64. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of BMY?

Bristol Myers Squibb has a price-to-earnings (P/E) ratio of about 14.02. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of BMY?

The market capitalisation of Bristol Myers Squibb is approximately $129.74B.

Is Bristol Myers Squibb profitable?

For its latest reported financial year, Bristol Myers Squibb recorded a net profit margin of about 14.64%.

Does BMY pay a dividend?

Bristol Myers Squibb currently has a dividend yield of about 3.94%.

What is the return on equity (ROE) of BMY?

Bristol Myers Squibb has a return on equity (ROE) of about 31.61%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of BMY?

Over the past 52 weeks, BMY has traded between a low of $42.52 and a high of $68.64.

Bristol Myers Squibb

BMY US Health Care Pharmaceuticals

S&P 500

$63.64

-0.17%

Delayed · cached 15 min

Fair value analysis

BMY

Bristol Myers Squibb

$63.64

Close used for this calculation

$86.54Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

59/100

Profitability17/25

Returns15/25

Balance Sheet9/25

Efficiency18/25

Growth19/25

Good

Quality radar

Consensus fair value

$86.54

Below FV

▲ +36.0% against the close used

Model range $29.13 – $134.37

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$29.13Fair value$86.54Bull$134.37

FairClose

52-week traded range

52W low $42.6052W high $68.09

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

Bristol Myers Squibb closed at $63.64, 26.5% below the consensus fair value of $86.54 drawn from 9 valuation models.

Financial DNA score 59/100 — Good. P/E of 18.4x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$125.06

+96.5%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

$29.13

-54.2%

√(22.5 × EPS × BVPS)

EPS=3.46, BVPS=10.9 · outside Graham range (P/E 18.4, P/B 5.8) — asset-light, treat as a rough floor

P/E Fair Value

$69.20

+8.7%

EPS × 20x (sector P/E)

EPS=3.46, Sector P/E=20x

Peter Lynch (PEG)

$43.22

-32.1%

EPS × Growth% (PEG = 1 is fair)

EPS=3.46, g=12.5%

EV/EBITDA

$89.31

+40.3%

(EBITDA × 16.2x − Net Debt) ÷ Shares

EBITDA=13.34B

Dividend Discount (DDM)

$134.37

+111.1%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=2.49, r=10%, g=8%

Book Value (P/B)

$69.77

+9.6%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=10.9, ROE=31.6%, g=6%, r=10%

Reverse DCF

$63.64

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 6% | Historical: 12.5%

Margin of Safety

$55.85

-12.2%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=74.46, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer